Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Multiple epidermotropic melanoma metastases developing during BRAF and MEK inhibitor therapy

Bibliographic Details
Main Authors:	Raphael Reinhard, MD, Christoffer Gebhardt, MD, Nolwenn Maurier, MD, Lionel Larribère, PhD, Azadeh Orouji, MD, Jochen Utikal, MD
Format:	Article
Language:	English
Published:	Elsevier 2018-03-01
Series:	JAAD Case Reports
Subjects:	BRAF MEK melanoma metastases targeted therapy
Online Access:	http://www.sciencedirect.com/science/article/pii/S2352512617302138

Similar Items

Immunological effects of BRAF+MEK inhibition
by: Paolo A. Ascierto, et al.
Published: (2018-09-01)

BRAF/MEK inhibitor-induced remission of primary cutaneous myoepithelial carcinoma after local recurrence
by: Jacqueline Guidry, MD, et al.
Published: (2020-08-01)

REPEATED USE OF BRAF AND MEK INHIBITORS IN METASTATIC MELANOMA PATIENTS AFTER PROFRESSION ON BRAF AND МЕК INHIBITORS. LITERATURE REVIEW AND CLINICAL OBSERVATION
by: I. V. Samoylenko, et al.
Published: (2017-11-01)

Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models
by: Anais Del Curatolo, et al.
Published: (2018-07-01)

Efficacy, Safety, and Tolerability of Approved Combination BRAF and MEK Inhibitor Regimens for <i>BRAF</i>-Mutant Melanoma
by: Omid Hamid, et al.
Published: (2019-10-01)

Safety of BRAF+MEK Inhibitor Combinations: Severe Adverse Event Evaluation
by: Tomer Meirson, et al.
Published: (2020-06-01)

BRAF and beyond: Tailoring strategies for the individual melanoma patient
by: Anthony Jarkowski, et al.
Published: (2014-01-01)

Clinical outcomes of BRAF plus MEK inhibition in melanoma: A meta‐analysis and systematic review
by: Qingliang Yu, et al.
Published: (2019-09-01)

Cardiovascular adverse events associated with BRAF versus BRAF/MEK inhibitor: Cross‐sectional and longitudinal analysis using two large national registries
by: Avirup Guha, et al.
Published: (2021-06-01)

BRAF Mutations and the Utility of RAF and MEK Inhibitors in Primary Brain Tumors
by: Karisa C. Schreck, et al.
Published: (2019-08-01)

Inhibition of Stearoyl-CoA desaturase 1 reverts BRAF and MEK inhibition-induced selection of cancer stem cells in BRAF-mutated melanoma
by: Maria Elena Pisanu, et al.
Published: (2018-12-01)

MEK inhibition and immune responses in advanced melanoma
by: Reinhard Dummer, et al.
Published: (2017-08-01)

Therapeutic efficacy and safety of combined BRAF and MEK inhibition in patients with malignant melanoma: a meta-analysis
by: Chen P, et al.
Published: (2017-11-01)

Case Report: Rechallenge With BRAF and MEK Inhibitors in Metastatic Melanoma: A Further Therapeutic Option in Salvage Setting?
by: Anna Stagno, et al.
Published: (2021-05-01)

BRAF and MEK inhibitors differentially affect nivolumab-induced T cell activation by modulating the TCR and AKT signaling pathways
by: Peng Yue, et al.
Published: (2019-01-01)

Efficacy of BRAF and MEK Inhibition in Patients with BRAF-Mutant Advanced Melanoma and Germline CDKN2A Pathogenic Variants
by: Francesco Spagnolo, et al.
Published: (2021-05-01)

Dabrafenib and Trametinib in BRAF Mutant Metastatic Conjunctival Melanoma
by: Ernesto Rossi, et al.
Published: (2019-04-01)

Mechanisms of resistance to BRAF and MEK inhibitors and clinical update of US Food and Drug Administration-approved targeted therapy in advanced melanoma
by: Kakadia S, et al.
Published: (2018-10-01)

Immunomodulatory Properties of BRAF and MEK Inhibitors Used for Melanoma Therapy—Paradoxical ERK Activation and Beyond
by: Thomas Jung, et al.
Published: (2021-09-01)

New features in MEK retinopathy
by: Pallavi Tyagi, et al.
Published: (2018-09-01)

Combined Therapy with Anti-PD1 and BRAF and/or MEK Inhibitor for Advanced Melanoma: A Multicenter Cohort Study
by: Sandra Huynh, et al.
Published: (2020-06-01)

Circulating Tumor DNA Correlates with Outcome in Metastatic Melanoma Treated by BRAF and MEK Inhibitors – Results of a Prospective Biomarker Study
by: Forschner A, et al.
Published: (2020-06-01)

Sensitivity to the MEK inhibitor E6201 in melanoma cells is associated with mutant <it>BRAF</it> and wildtype <it>PTEN</it> status
by: Byron Sara A, et al.
Published: (2012-10-01)

Rapid and dramatic responses to dabrafenib and trametinib in BRAF V600E‐mutated lung adenocarcinoma
by: Takayo Ota, et al.
Published: (2021-10-01)

Baseline Genomic Features in <i>BRAFV600</i>-Mutated Metastatic Melanoma Patients Treated with BRAF Inhibitor + MEK Inhibitor in Routine Care
by: Baptiste Louveau, et al.
Published: (2019-08-01)

Usefulness of monitoring circulating tumor cells as a therapeutic biomarker in melanoma with BRAF mutation
by: Yukiko Kiniwa, et al.
Published: (2021-03-01)

Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care
by: Markus V. Heppt, et al.
Published: (2017-08-01)

A Rare Complex BRAF Mutation Involving Codon V600 and K601 in Primary Cutaneous Melanoma: Case Report
by: Francesca Consoli, et al.
Published: (2020-07-01)

Growth hormone receptor promotes breast cancer progression via the BRAF/MEK/ERK signaling pathway
by: Xiaojue Zhu, et al.
Published: (2020-06-01)

MEK inhibitors for the treatment of NRAS mutant melanoma
by: Sarkisian S, et al.
Published: (2018-08-01)

The Role of Treatment Sequencing with Immune-Checkpoint Inhibitors and BRAF/MEK Inhibitors for Response and Survival of Patients with BRAFV600-Mutant Metastatic Melanoma—A Retrospective, Real-World Cohort Study
by: Ebner, R., et al.
Published: (2022)

Intra-patient Heterogeneity of BRAF and NRAS Molecular Alterations in Primary Melanoma and Metastases
by: Cristina Pellegrini, et al.
Published: (2020-01-01)

Significance of BRAF Kinase Inhibitors for Melanoma Treatment: From Bench to Bedside
by: Taku Fujimura, et al.
Published: (2019-09-01)

Combination therapies to inhibit the RAF/MEK/ERK pathway in melanoma: we are not done yet.
by: Grant A. McArthur
Published: (2015-07-01)

BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy
by: Jan Dörrie, et al.
Published: (2018-01-01)

ROS production induced by BRAF inhibitor treatment rewires metabolic processes affecting cell growth of melanoma cells
by: Giulia Cesi, et al.
Published: (2017-06-01)

Clinico-economic analysis of PD-1 inhibitors and combinations of BRAF and MEK inhibitors for the treatment of metastatic melanoma with a BRAF V600 gene mutation
by: D. Yu. Belousov, et al.
Published: (2018-07-01)

BRAF inhibitors and radiotherapy for melanoma brain metastases: potential advantages and disadvantages of combination therapy
by: Chowdhary M, et al.
Published: (2016-12-01)

Antitumor effects of the investigational selective MEK inhibitor TAK733 against cutaneous and uveal melanoma cell lines
by: von Euw Erika, et al.
Published: (2012-04-01)

Real-World Experience with Targeted Therapy in BRAF Mutant Advanced Melanoma Patients: Results from a Multicenter Retrospective Observational Study Advanced Melanoma in Russia (Experience) (ADMIRE)
by: Kristina V. Orlova, et al.
Published: (2021-05-01)